文献速递角膜与眼表疾病

抗EMP2抗体阻断可减少小鼠角膜新生血管

Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

该研究在小鼠角膜碱烧伤模型中,通过结膜下注射抗EMP2抗体、对照抗体或生理盐水,比较对角膜新生血管的抑制作用。结果显示抗EMP2抗体较对照抗体或溶剂显著减少新生血管临床评分、中央角膜厚度及组织学新生血管、CD34和CD31染色。体外实验显示抗EMP2阻断抗体可降低角膜缘细胞EMP2表达、VEGF表达与分泌及细胞迁移。

要点

  • 抗EMP2抗体结膜下注射可显著减轻小鼠角膜碱烧伤后新生血管。
  • 组织学显示抗EMP2抗体减少新生血管及CD34、CD31染色。
  • 体外抗EMP2阻断抗体降低角膜缘细胞EMP2、VEGF表达分泌及迁移。

核心结论

  • 在小鼠角膜碱烧伤模型中,EMP2可作为病理性角膜新生血管的新靶点,抗EMP2抗体阻断具有潜在治疗价值。

研究设计与样本

  • 采用小鼠单侧角膜NaOH碱烧伤的体内模型,伤后结膜下注射抗EMP2抗体、对照抗体或无菌生理盐水。
  • 碱烧伤后7天进行新生血管临床评分,随后摘眼行组织学分析及VEGF、CD31、CD34免疫染色。
  • 体外将角膜缘细胞与抗EMP2阻断抗体孵育,检测EMP2表达、VEGF表达与分泌及细胞迁移。

主要发现

  • 抗EMP2抗体较对照抗体或溶剂显著降低新生血管临床评分和中央角膜厚度。
  • 抗EMP2抗体组组织学新生血管减少,CD34染色和CD31染色均降低。
  • 体外抗EMP2阻断抗体显著降低角膜缘细胞EMP2表达、VEGF表达与分泌及细胞迁移。

临床怎么用

  • 该动物模型结果支持将EMP2抗体阻断作为角膜病理性新生血管的潜在新治疗方向进一步研究。

局限性

  • 研究仅基于小鼠角膜碱烧伤模型及体外角膜缘细胞实验,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pathologic corneal neovascularization is a major cause of blindness worldwide, and treatment options are currently limited. VEGF is one of the critical mediators of corneal neovascularization but current anti-VEGF therapies have produced limited results in the cornea. Thus, additional therapeutic agents are needed to enhance the antiangiogenic arsenal. Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma. In this paper, we investigate the efficacy of anti-EMP2 immunotherapy in the prevention of corneal neovascularization. METHODS: An in vivo murine cornea alkali burn model was used to study pathologic neovascularization. A unilateral corneal burn was induced using NaOH, and subconjunctival injection of either anti-EMP2 antibody, control antibody, or sterile saline was performed after corneal burn. Neovascularization was clinically scored at 7 days postalkali burn, and eyes were enucleated for histologic analysis and immunostaining including VEGF, CD31, and CD34 expression. RESULTS: Anti-EMP2 antibody, compared to control antibody or vehicle, significantly reduced neovascularization as measured by clinical score and central cornea thickness, as well as by histologic reduction of neovascularization, decreased CD34 staining, and decreased CD31 staining. Incubation of corneal limbal cells in vitro with anti-EMP2 blocking antibody significantly decreased EMP2 expression, VEGF expression and secretion, and cell migration. CONCLUSIONS: This work demonstrates the effectiveness of EMP2 as a novel target in pathologic corneal neovascularization in an animal model and supports additional investigation into EMP2 antibody blockade as a potential new therapeutic option.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Sun MM, Chan AM, Law SM, et al. Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model. Invest Ophthalmol Vis Sci. 2019. PMID: 30646013. doi:10.1167/iovs.18-24345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。